An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK

被引：0
|
作者：
Ágnes Benedict
David A. Cameron
Hélène Corson
Stephen E. Jones
机构：
[1] United BioSource Corporation,Department of Medical Oncology
[2] Leeds University,undefined
[3] Sanofi-Aventis Research & Development,undefined
[4] US Oncology Research,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Overall Survival; Paclitaxel; Docetaxel; Metastatic Breast Cancer; Indirect Comparison;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Paclitaxel and docetaxel have been available for the treatment of metastatic breast cancer (MBC) since the 1990s. However, until very recently, comparisons between these two drugs have been difficult due to lack of direct comparative clinical evidence and differences in trial patient populations.
引用
收藏
页码：847 / 859
页数：12
相关论文
共 50 条
  • [1] An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK
    Benedict, Agnes
    Cameron, David A.
    Corson, Helene
    Jones, Stephen E.
    PHARMACOECONOMICS, 2009, 27 (10) : 847 - 859
  • [2] ECONOMIC EVALUATION OF PACLITAXEL ALBUMIN, PACLITAXEL, AND DOCETAXEL AS A SECOND LINE TREATMENT FOR METASTATIC BREAST CANCER
    Gharaibeh, M.
    Malone, D. C.
    VALUE IN HEALTH, 2014, 17 (07) : A640 - A640
  • [3] Cost-effectiveness of docetaxel compared to paclitaxel in metastatic breast cancer: A UK health economic analysis
    Jones, S. E.
    Benedict, A.
    Cameron, D.
    Jourdan, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Two regimens of docetaxel for metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 7 - 7
  • [5] Comparison of Docetaxel with Paclitaxel for the metastatic breast cancer
    Huober, J
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2006, 66 (01) : 87 - 89
  • [6] Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer
    Eniu, A
    Palmieri, FM
    Perez, EA
    ONCOLOGIST, 2005, 10 (09): : 665 - 685
  • [7] Economic evaluation of docetaxel for breast cancer
    Lwin, Zarnie
    Leighl, Natasha
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (02) : 283 - 290
  • [8] Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
    Rajappa, Senthil
    Joshi, Ashish
    Doval, Dinesh C.
    Batra, Ullas
    Rajendranath, Rejiv
    Deo, Avinash
    Biswas, Ghanshyam
    Bajpai, Peush
    Tilak, T. V. S.
    Kane, Sriram
    Kumar, Kishore
    Kumar, Manish
    Talele, Avinash D.
    Devde, Prakash
    Gupta, Ashutosh
    Joshi, Nisarg
    Sejpal, Jaykumar
    Bunger, Deepak
    Khan, Mujtaba
    ONCOLOGY LETTERS, 2018, 16 (03) : 3757 - 3769
  • [9] Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer
    Jones, S
    Erban, J
    Overmoyer, B
    Budd, GT
    Hutchins, XL
    Lower, E
    Laufman, L
    Sundaram, S
    Urba, W
    Olsen, S
    Meyers, ML
    Ravdin, PM
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S9 - S9
  • [10] Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
    Gharaibeh, M.
    McBride, A.
    Bootman, J. L.
    Abraham, I.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1301 - 1305
12345